The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 24, 2025

Filed:

Nov. 10, 2021
Applicant:

Accerelon Pharma Inc., Cambridge, MA (US);

Inventors:

Ravindra Kumar, Cambridge, MA (US);

Asya Grinberg, Cambridge, MA (US);

Dianne Sako, Cambridge, MA (US);

Assignee:

Accerelon Pharma Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/71 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/71 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01);
Abstract

In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used for the treatment or prevention of various TGF-beta associated conditions, including without limitation diseases and disorders associated with, for example, cancer, muscle, bone, fat, red blood cells, metabolism, fibrosis and other tissues that are affected by one or more ligands of the TGF-beta superfamily.


Find Patent Forward Citations

Loading…